The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1110
August 6, 2001
View Complete Issue         Table of Contents 2019 
Insulin Glargine (Lantus), A New Long-acting Insulin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Insulin Glargine (Lantus), A New Long-acting Insulin
August 6, 2001 (Issue: 1110)
Insulin Glargine (Lantus) is a new long-acting human insulin analog approved by the FDA for treatment of both type 1 and type 2 diabetes. Synthesized by recombinant DNA technology, it differs from human insulin at position 21 in the A-chain where...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Glargine (Lantus), A New Long-acting Insulin
Article code: 1110a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.